Please login to the form below

Not currently logged in
Email:
Password:

GSK submits two new flu vaccines for regulatory approval

Seeks licences for quadrivalent influenza vaccine and pandemic influenza vaccine

GlaxoSmithKline (GSK) has filed two new influenza vaccines for regulatory approval.

Its quadrivalent influenza vaccine, which has yet to be approved in its first market, has been submitted to the US Food and Drug Adminstration (FDA) and the European Medicines Agency (EMA).

GSK is seeking approval for the vaccine to be used in adults and children from three years of age against influenza disease caused by influenza virus types A and B that are contained in the vaccine.

The pharma company submitted a supplemental Biologics License Application to the FDA and filed a new application to the EMA.

Pandemic flu vaccine

Meanwhile, GSK has also submitted its H5N1 pandemic flu vaccine to the FDA for use in adults “as directed by the US Government”.

GSK's H5N1 influenza vaccine programme was supported by a development contract with the Biomedical Advanced Development and Research Authority (BARDA) of the US Department of Health and Human Services.

That vaccine was approved in March, 2011 in Europe, where it is marketed under the brand name Pumarix and GSK's biologics unit has a five-year marketing authorisation from the European Commission.

6th March 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Shining our spotlight on… the patient
The second issue of our new SPOTLIGHT ON series is live! In this issue, we discuss the role of patient insights and what impact it has on improving patient outcomes...
Healthcare in the Digital Age
Healthcare is changing. By understanding the needs of the physicians, and using innovative channels to make meaningful connections, pharma can ensure it continues to enjoy a mutually beneficial relationship....
Opinion piece: Patient-centricity and pharma – where are we now?
Patient-centricity is a term that has gained currency in the pharma industry in recent years, and most major companies in the sector are now dedicating resources to ensure that they...

Infographics